Accelerate Diagnostics Inc  

(Public, NASDAQ:AXDX)   Watch this stock  
Find more results for NYSEAMEX:AXK
-0.24 (-1.19%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.31 - 20.69
52 week 14.51 - 31.86
Open 20.31
Vol / Avg. 311,804.00/192,172.00
Mkt cap 902.90M
P/E     -
Div/yield     -
EPS -0.63
Shares 44.61M
Beta 0.76
Inst. own 31%
Mar 4, 2015
Accelerate Diagnostics Inc at Cowen Health Care Conference - 8:00AM EST - Add to calendar
Jan 13, 2015
Accelerate Diagnostics Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -55087.50% -31645.93%
Operating margin -55168.75% -31706.05%
EBITD margin - -30931.89%
Return on average assets -45.05% -53.86%
Return on average equity -46.83% -57.04%
Employees 47 -
CDP Score - -


Ste 470 Bldg 3-307 3950 S Country Club Rd
TUCSON, AZ 85714-2240
United States - Map
+1-303-8638088 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Accelerate Diagnostics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing instrumentation for the identification and antibiotic susceptibility testing of infectious pathogens. The Company�s BACcel platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies. The Company�s BACcel system includes a fixed instrument and proprietary single-use test cassettes. Each cassette tests a single patient specimen and is then discarded. BACcel uses long-accepted bacteriological testing principles, but applies its technology to adapt them to analyze live bacteria extracted directly from a patient specimen. The Company�s other product includes OptiChem, which is used in micro arraying components. OptiChem offers noise rejection (non-specific binding by interfering substances) and capacity for target binding. OptiChem also offers the ability to apply micro-patterns, enabling analyzer designs.

Officers and directors

John Patience Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Lawrence Mehren President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Steve Reichling Chief Financial Officer
Age: 35
Bio & Compensation  - Reuters
Pete Bantock Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Mark C. Miller Independent Director
Age: 58
Bio & Compensation  - Reuters
Jack W. Schuler Independent Director
Age: 73
Bio & Compensation  - Reuters
Matthew W. Strobeck Ph.D. Independent Director
Age: 41
Bio & Compensation  - Reuters
Frank J. M. ten Brink Independent Director
Age: 57
Bio & Compensation  - Reuters